DOP076 Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab

  • Feagan B
  • Colombel J
  • Rubin D
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: In the GEMINI 1 study (NCT00783718), vedolizumab (VDZ) significantly improved Inflammatory Bowel Disease Questionnaire (IBDQ) total score in patients with ulcerative colitis (UC) compared with placebo (PBO). VDZ effects on health-related quality of life (HRQoL) were also assessed with the 36-Item Short Form Health Survey (SF-36) and EQ-5DTM visual analogue scale (VAS) for the overall population and IBDQ total and SF-36 summary scores for population subgroups based on prior anti-tumour necrosis factor (TNF) therapy status and baseline Mayo score. Methods: In weeks 0-6 of the GEMINI 1 study, patients received blinded VDZ 300 mg or PBO or open-label VDZ 300 mg at weeks 0 and 2. Week 6 responders were rerandomised to receive VDZ 300 mg every 4 weeks (Q4W) or 8 weeks (Q8W) or PBO Q4W during the maintenance phase (weeks 6-52). Changes from baseline to weeks 6 and 52 in HRQoL end points were analysed for the overall population prospectively and by baseline Mayo score (<9, >9) and prior anti-TNF therapy (failure, naive) as post hoc analyses. Proportions of patients with an IBDQ total score >170 and those with clinically meaningful increases from baseline in IBDQ total score (>16 points) and SF-36 mental (MCS) or physical component summary scores (PCS; >5 points) were also assessed. Analyses used the last-observation-carriedforward method. Results: At weeks 6 and 52, VDZ patients had significant improvements from baseline in SF-36 PCS and MCS and EQ-5D VAS scores vs PBO patients (Table). VDZ improved IBDQ total and SF-36 PCS and MCS scores compared with PBO at weeks 6 and 52 for Mayo score <9 and anti-TNF-naive patient subgroups. For patients with Mayo score >9, VDZ improved IBDQ total and SF-36 MCS scores at week 6 and IBDQ total and SF-36 PCS and MCS scores at week 52 (Q8W only) compared with PBO. Improvements vs PBO in IBDQ total and SF-36 PCS scores were seen at week 6 in VDZ patients with prior anti-TNF failure. Proportions of patients with IBDQ total score >170 were higher with VDZ at week 6 and week 52 than with PBO (P <0.005) and higher proportions of VDZ-treated than PBO-treated patients had clinically meaningful increases from baseline in IBDQ total (weeks 6 and 52), SF-36 PCS (weeks 6 and 52 [Q8W only]), and SF-36 MCS (week 6) scores. Conclusions: Patients with UC treated with VDZ had significant and clinically meaningful improvements in HRQoL, as measured by both disease-specific and generic instruments, at weeks 6 and 52 compared with PBO across disease severity and in difficult-to-treat UC. (Table Presented).

Cite

CITATION STYLE

APA

Feagan, B., Colombel, J.-F., Rubin, D., Mody, R., Sankoh, S., & Lasch, K. (2014). DOP076 Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab. Journal of Crohn’s and Colitis, 8, S51–S52. https://doi.org/10.1016/s1873-9946(14)60101-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free